Status:
COMPLETED
Adherence in Pediatric Multiple Sclerosis
Lead Sponsor:
The Hospital for Sick Children
Collaborating Sponsors:
National Multiple Sclerosis Society
Loma Linda University
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
10-18 years
Phase:
NA
Brief Summary
Disease modifying therapies (DMT) are widely used for children and adolescents with MS. Nonetheless, many pediatric patients continue to relapse and therefore require changes in therapy. We designed t...
Eligibility Criteria
Inclusion
- Adolescent boys/girls who are 10 to 17 years 11 months old;
- Have a diagnosis of MS, as per revised McDonald diagnostic criteria and International Pediatric MS Study Group criteria;
- Prescribed with an oral or injectable disease-modifying therapy for MS for at least six months.
Exclusion
- Have non-specific white matter abnormalities and metabolic or infectious etiologies for white matter abnormalities. This is indicative of not having a true diagnosis of MS.
- Patients on IV DMT will not be included in the study.
- Non-English speaking patients
Key Trial Info
Start Date :
January 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2016
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT02234713
Start Date
January 1 2013
End Date
September 1 2016
Last Update
January 18 2020
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama
Birmingham, Alabama, United States, 35294
2
Loma Linda University
Loma Linda, California, United States, 92354
3
The Regents of the University of California, San Francisco
San Francisco, California, United States, 94143
4
University of Colorado at Denver
Denver, Colorado, United States, 80202